Clinical Trial

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-25; most recent amendment 2025-04-17.
Trial Details
NCT Number NCT06339658
Lead Sponsor Hospital Universitari de Bellvitge
Conditions Breast Cancer, Axillary Metastases
Enrollment 43 participants
Start Date 2021-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-22